Regeneron’s Kevzara (Sarilumab) Gains the US FDA’s Approval to Treat Active Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Shots:
- The US FDA has granted approval to Kevzara (sarilumab) for treating active polyarticular juvenile idiopathic arthritis patients (≥63kg wt.)
- The approval was based on studies assessing the drug’s safety and effectiveness in adults with rheumatoid arthritis and pediatric patients with pJIA. New ARs were not found with the most common ones in pJIA population being nasopharyngitis, neutropenia, upper respiratory tract infection & injection site erythema; neutropenia resulted in permanent discontinuation
- Kevzara works by binding and inhibiting IL-6-mediated signaling that leads to joint destruction and other systemic problems in rheumatoid arthritis patients
Ref: Regeneron | Image: Regeneron
Related News:- Regeneron and Sanofi Receive the US FDA’s Approval for Kevzara (sarilumab) to Treat Polymyalgia Rheumatica
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
